MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MAB Discovery GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11210
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats by employing biochemical and cellular based screens. It relies on natural immune response and B cell cloning techniques for the production of monoclonals with unprecedented epitope coverage and potency. MAB Discovery’s B-cells are cloned by fluorescence activated cell sorting and deposited as single cells into proprietary growth medium. It also undertakes projects from immunization, high throughput screening, assay development, and functional characterization. The company partners with biotech and pharmaceutical companies for the discovery and generation of monoclonal antibodies. MAB Discovery is headquartered in Neuried, Germany.

MAB Discovery GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Licensing Agreements 17
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH – Key Competitors 19
MAB Discovery GmbH – Key Employees 20
MAB Discovery GmbH – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Other Significant Developments 22
Jun 20, 2018: Ongoing discussions with MAB Discovery for revised collaboration agreement Advance notice of termination of existing agreement in-line with discussions 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Key Facts 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH, Key Competitors 19
MAB Discovery GmbH, Key Employees 20

List of Figures
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Optimum General Inc.:企業の戦略・SWOT・財務分析
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Steel Authority Of India Ltd:企業の戦略・SWOT・財務分析
    Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority Of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Alvogen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Alvogen Inc (Alvogen) develops, manufactures and markets biosimilar products, generic pharmaceuticals and OTC products. The company’s product portfolio comprises generic medications in various therapeutic areas that include oncology, cardiology, respiratory, neurology and gastroenterology. A …
  • Dottikon ES Holding AG (DESN):製薬・医療:M&Aディール及び事業提携情報
    Summary Dottikon ES Holding AG (Dottikon) manufactures and commercializes active pharmaceutical ingredients (APIs), performance chemicals and intermediates for chemical and pharmaceutical industries. The company finds novel uses for hazardous reactions and continuous processing that facilitate the r …
  • Cameco Corporation:企業の戦略・SWOT・財務分析
    Cameco Corporation - Strategy, SWOT and Corporate Finance Report Summary Cameco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • numares AG:企業の製品パイプライン分析2018
    Summary Numares AG (Numares), formerly Numares GmbH, is a developer and marketer of products for life science research and clinical diagnostics. The company’s AXINON lipoFIT, a test system used for lipoprotein profiling, while insightLP provides insights into lipid related research using lipoprotein …
  • Air Products and Chemicals Inc (APD):企業の財務・戦略的SWOT分析
    Air Products and Chemicals Inc (APD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Banca Dello Stato Del Cantone Ticino:企業の戦略・SWOT・財務分析
    Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report Summary Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Wellington Management Company LLP:企業のM&A・事業提携・投資動向
    Wellington Management Company LLP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wellington Management Company LLP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Aurora Energy Pty Ltd:企業の戦略・SWOT・財務分析
    Aurora Energy Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Aurora Energy Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Solvay Group:企業の戦略・SWOT・財務情報
    Solvay Group - Strategy, SWOT and Corporate Finance Report Summary Solvay Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • NTT DOCOMO Inc:企業の戦略・SWOT・財務分析
    NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report Summary NTT DOCOMO Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • NanoSmart Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary NanoSmart Pharmaceuticals Inc (NanoSmart) focuses on the development of novel methods for the treatment of cancer and other diseases. The company is evaluating a human-derived anti-nuclear antibody which targets areas of necrosis presence in various different types of cancer tumors. Its prop …
  • Teck Resources Ltd:企業のM&A・事業提携・投資動向
    Teck Resources Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teck Resources Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Helius Medical Technologies Inc (HSM):企業の製品パイプライン分析2018
    Summary Helius Medical Technologies Inc (HMT) is a medical device company that provides neurological wellness solutions. The company provides development, licensing and acquisition of non-invasive platform technologies for amplifying the brain’s ability to heal itself. It provides development of tec …
  • Union Jack Oil plc (UJO):企業の財務・戦略的SWOT分析
    Summary Union Jack Oil Plc (Union Jack Oil), formerly Union Jack Oil Ltd is an onshore oil and gas company that offers exploration and development of hydrocarbon projects. The company develops its portfolio of oil and gas assets by acquiring interests in drill ready prospects. It holds license inter …
  • DiaMedica Therapeutics Inc (DMA):企業の財務・戦略的SWOT分析
    Summary DiaMedica Therapeutics Inc (DiaMedica) formerly DiaMedica Inc, is a clinical-stage bio pharmaceutical company which develops innovative medicines for the treatment neurological and kidney diseases. Its lead product candidate DM-199, is a human recombinant protein that treats diabetes type 1 …
  • Ardelyx Inc (ARDX):企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Innsuites Hospitality Trust
    Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report Summary Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • T7 Global Berhad (T7GLOBAL):石油・ガス:M&Aディール及び事業提携情報
    Summary T7 Global Berhad (T7 Global), formerly Tanjung Offshore Berhad, is an oil and gas company that offers gas generators and integrated services. The company's services include topside maintenance, engineering and procurement, installation and commissioning, initial engineering design layout, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆